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Abstract
Heparin is a polysaccharide that is widely used as an anticoagulant drug. The mechanism for 
heparin’s anticoagulant activity is primarily through its interaction with a serine protease inhibitor, 
antithrombin III (AT), that enhances its ability to inactivate blood coagulation serine proteases, 
including thrombin (factor IIa) and factor Xa. The AT-binding site in the heparin is one of the most 
well-studied carbohydrate-protein binding sites and its structure is the basis for the synthesis of the 
heparin pentasaccharide drug, fondaparinux. Despite our understanding of the structural 
requirements for the heparin pentasaccharide AT-binding site, there is a lack of data on the natural 
variability of these binding sites in heparins extracted from animal tissues. The present work 
provides a detailed study on the structural variants of the tetrasaccharide fragments of this binding 
site afforded following treatment of a heparin with heparin lyase II. The 5 most commonly 
observed tetrasaccharide fragments of the AT-binding site are fully characterized, and a method for 
their quantification in heparin and low-molecular-weight heparin products is described.
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Introduction
Despite having been discovered 100 years ago by a medical student in 1916,1 the structure 
of the clinical anticoagulant heparin is still not completely understood.2 Heparin (and the 
related glycosaminoglycan heparan sulfate) is a linear polysaccharide comprised of 1→4-
glycosidically linked alternating uronic acid (UA), α-L-iduronic acid (IdoA) or β-D-
glucuronic acid (GlcA), and α-D-glucosamine (GlcN) residues.2 The UA residues can be 
substituted with 2-O-sulfogroups and the GlcN residues can be unsubstituted or substituted 
with N-sulfo or N-acetyl groups and 3-O-sulfo, and/or 6-O-sulfo group substituted.2
These sulfo group substitutions take place within the Golgi during biosynthesis through the 
action of sulfotransferases (STs).3,4 In mammals, there are multiple isoforms of N-
deacetylase, N-sulfotransferases (NDSTs), 3-O-sulfotransferases (3OSTs), and 6-O-
sulfotransferases (6OSTs) but only single isoforms of 2-O-sulfotransferase http://dx.doi.org/
10.1016/j.xphs.2016.11.023 (2OST).4 The action of 3OST is believed to be the last step in 
heparin biosynthesis and the action of different 3OST isoforms appears to impart specialized 
functions to heparin chains.5–7 For example, the action of 3OST-1 is responsible for the 
biosynthesis of anticoagulant-active heparin whereas the action of 3OST-5 results in the 
biosynthesis of nervous tissue heparan sulfate that serves as a coreceptor for herpes simplex 
virus5 and multiple isoforms are involved in the biosynthesis of follicular heparan sulfate 
important in ovulation.7
Heparin’s anticoagulant activity depends on its interaction with the serine protease inhibitor, 
antithrombin III (AT), which on binding to heparin undergoes a conformational change that 
enhances its ability to irreversibly inhibit coagulation serine proteases, including thrombin 
and factor Xa.8 Heparin-AT binding is one of the most well studied carbohydrate-protein 
interactions and depends on a specific type of pentasaccharide sequence9 within heparin that 
contains a 3-O-sulfo group in its central GlcN residue.10 There is some reported structural 
variability in this pentasaccharide sequence11,12 particularly associated with heparins from 
different tissues or species.13
Pharmaceutical heparins are currently extracted from the tissues of food animals that are rich 
in the mast cells that biosynthesize heparin.14 The major source of heparin today is porcine 
intestinal mucosa, but in the past, heparin has been prepared from bovine lung and bovine 
intestinal mucosa.15 Moreover, there is current interest in the chemoenzymatic synthesis of 
non–animal-sourced heparins.16 In 2007, pharmaceutical heparin was contaminated with a 
toxic semisynthetic glycosaminoglycan, oversulfated chondroitin sulfate.17 Furthermore, 
there is a growing concern that much of the heparin comes from a single species and is 
sourced from a single country.18 Thus, the US Food and Drug Administration has 
recommended the development of other heparin sources to address the current fragile supply 
chain for this critical drug.18
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The present study examines the structural variability of the AT-binding sites within heparin. 
Heparins from different sources and low-molecular-weight heparins (LMWHs), prepared 
through the controlled depolymerization of pharmaceutical heparin,19,20 were 
depolymerized through exhaustive treatment with the enzyme heparin lyase II.21 The 
resulting resistant tetrasaccharides containing 3-O-sulfo groups22 were isolated, purified, 
and characterized using mass spectrometry (MS), tandem MS (MS/MS), and nuclear 
magnetic resonance spectroscopy (NMR). Five tetrasaccharide structures were determined, 
which provide an important insight into the structural variability of the AT-binding site 
within pharmaceutical heparins. A high performance liquid chromatography (HPLC)-MS 
assay was also developed that allows quantification of these 3-O-sulfo group 
tetrasaccharides.
A detailed understanding of the possible biosynthetic variability in the AT-binding site 
structure is necessary for the development of a detailed structure-activity relationship. The 
chemically synthesized drug Arixtra® (fondaparinux) has been successfully used as a highly 
selective anticoagulant for over 2 decades.23 The structure of Arixtra® is based on a single 
structural variant of the AT-pentasaccharide binding site.10 Chemoenzymatic synthesis has 
reduced the number of synthetic steps for the efficient synthesis of this and other variant AT-
binding sites.24,25 This study is aimed at increasing the number of targets for directed 
chemoenzymatic synthesis.
Results and Discussion
Preparation of Tetrasaccharides From Porcine Intestinal Mucosal Heparin
Heparin was treated exhaustively with recombinantly expressed heparin lyase II.26 This 
enzyme is known to show the least selectivity among the 3 Flavobacterial heparin 
lyases21,27,28 cleaving both highly sulfated and undersulfated domains within heparin.27,28 
Despite its broad specificity, certain tetrasaccharides are resistant to heparin lyase II 
digestion.22 While fully sulfated, hexasulfated tetrasaccharide, ΔUA2S (1→4) GlcNS6S 
(1→4) IdoA2S (1→4) GlcNS6S (where ΔUA is deoxy-α-L-threo-hex-4-
enopyranosyluronic acid), can be cleaved by heparin lyase II into 2 molecules of ΔUA2S 
(1→4) GlcNS6S. This step required long reaction time and large amount of enzyme. In 
contrast, tetrasaccharides containing a 3-O-sulfo group on their reducing-end GlcN residue 
are completely resistant to heparin lyase II digestion.22 Thus, as expected, exhaustive 
digestion with heparin lyase II afforded primarily di-saccharides together with a minor 
amount of heparin lyase II–resistant tetrasaccharides. A Bio-Gel P2 size-exclusion column 
afforded a good separation of disaccharides from resistant tetrasaccharides and heparin lyase 
II protein (Supplementary Fig. S1).
Further purification of the tetrasaccharides was carried out by semipreparative strong anion 
exchange (SAX)-HPLC (Fig. 1). Initially, a gradient elution was used to remove other 
products from a mixture containing primarily tetrasaccharides. The tetrasaccharide-
containing mixture was recovered, desalted, and reapplied using an optimized gradient to 
obtain the individual tetrasaccharide. Approximately 25 prominent peaks were examined by 
MS after desalting. From the MS, we found that some peaks contained disaccharides or 
trisaccharides. The tetrasaccharide-containing peaks were repurified by SAX-HPLC. As 
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expected, exhaustive heparin lyase II treatment failed to digest some tetrasaccharides that 
did not contain 3-O-sulfo groups, such as the hexasulfated tetrasaccharide.29 Retreatment of 
these tetrasaccharides, however, showed that they were sensitive to heparin lyase II. Only 5 
tetrasaccharides were completely resistant to heparin lyase II and their purity was assessed 
to be >90% by analytical SAX-HPLC (Supplementary Fig. S2). These all most likely are 
afforded as the direct result of heparin biosynthesis because the conditions, used in the 
preparation of heparin and these tetrasaccharides, are considerably milder than the 
conditions required for the degradative loss of sulfate groups from heparin.30
Characterization of the Tetrasaccharides by MS
MS analysis provided initial structural information on 5 heparin lyase II–resistant 
tetrasaccharides (Supplementary Figs. S3a–S3e, tetrasaccharides 1–5). MS analysis showed 
the basic structures of the tetrasaccharides (Table 1): tetrasaccharide 1 (1) with the molecular 
mass of 956.07 was composed of ΔUA-GlcN-UA-GlcN +Ac + 3SO3; tetrasaccharide 2 (2) 
with the molecular mass of 1035.01 was composed of ΔUA-GlcN-UA-GlcN + Ac + 4SO3; 
tetrasaccharide 3 (3) with the molecular mass of 1072.97 was composed of ΔUA-GlcN-UA-
GlcN + 5SO3; tetrasaccharide 4 (4) with the molecular mass of 1115.01 was composed of 
ΔUA-GlcN-UA-GlcN + Ac + 5SO3; and tetrasaccharide 5 (5) with the molecular mass of 
1152.95 was composed of ΔUA-GlcN-UA-GlcN + 6SO3. The retention times on SAX-
HPLC increased with the total number of sulfo (S) groups.
MS/MS analysis was next used to examine the structure of each tetrasaccharide (Fig. 2). 
Negative mode electrospray ionization (ESI) of each tetrasaccharide produced abundant 
multiply charged precursor ions allowing for efficient activation of their molecular ions. We 
have considered mostly sodium-adducted precursor ions for this analysis to reduce the 
decomposition of the labile sulfate groups on the tetrasaccharides31 during ion activation.
The MS/MS of 1 shows the annotated structure for collisionally induced dissociation (CID) 
fragmentation of the [M-5H+2Na]3− precursor ion at m/z 332.3416 (Fig. 2a). This ionized 
state allows for all the ionizable protons to be deprotonated. The 6-O-sulfogroup on the 
internal N-acetylglucosamine (GlcNAc) residue is assigned with a combination of both 
cross-ring and glycosidic product ions. The mass difference between C1/B1 and C2/B232 
identifies a sulfo group on the GlcNAc whereas the mass difference between product 
ions 2,4A2 and 0,2A2 or 0,3A2 and B2 specifically locates the sulfo group at the 6-O-position. 
The 2 sulfo groups on the reducing end GlcN residue are assigned using the masses of Y1 or 
Z1. The 3-O-sulfo on the GlcNS is assigned using the mass difference between the C3 
and 2,4A4 ions respectively.
The MS/MS of 2 produced abundant [M-6H+2Na]4− m/z 268.9936 for electron-detachment 
dissociation (EDD) activation. Again with the aid of Na/H, we are able to ionize all 
ionizable protons. Good structural coverage was observed allowing assignment of the 
structure of the compound (Fig. 2b). The mass difference between B1 or C1 and B2 and C2 
identifies a sulfo group on the internal GlcNAc. The mass difference between product 
ions 0,3A2 and C2 assigns the 6-O-sulfo group on the GlcNAc. The GlcN residue at the 
reducing end containing 3 sulfo groups is confidently assigned with glycosidic product ion 
Y1. Cross-ring ions 1,4X0 and 0,2X0 specifically locates the 6-O- and N-sulfo groups.
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The MS/MS of 3 relied on CID product ion assignment (Fig. 2c). CID activation of the 
[M-6H+2Na]4− at m/z 278.4802 produced enough glycosidic and cross-ring cleavages for 
structural analysis. Accurate mass difference between glycosidic ions C1 and C2 locates 2 
sulfo groups on the internal GlcN residue at the N- and 6-O-positions. The exact positions of 
these sulfo groups are assigned using the mass difference between products ions 2,4A2 
and 0,2A2, and B2 and 0,2A2, respectively. The mass of the glycosidic cleavage Y1 locates 3 
sulfo groups on the reducing end GlcN. The 3-O-sulfo group on the reducing end GlcN is 
confirmed by accurate mass difference between fragment ions Y1 and 2,4X0. The mass 
of 2,4X0 can also confirm the presence of 2 sulfo groups at the 6-O- and N-positions 
with 0,2A4 specifically locating the N-sulfo group.
The MS/MS of 4, a pentasulfated tetrasaccharide, is shown in Figure 2d. The molecular ion 
[M-6H+2Na]4− at m/z 288.9830 was subjected to CID activation and generated structurally 
informative ions for assigning the structure. The mass of glycosidic ions B1 and C1 provided 
evidence for a nonreducing end–sulfated UA (ΔUA2S). The mass difference between B2/C2 
and B1/C1 identified a sulfo group on the internal GlcNAc. This sulfo group was on the 6-O-
position as confirmed with the accurate mass difference between cross-ring product 
ions 0,2A2 and 2,4A2. Again, we assigned the reducing end GlcN residue having 3 sulfo 
groups from Z1 and Y1. The exact positions of the sulfo groups are confirmed with multiple 
cross-ring cleavages as shown in Figure 2d.
The MS/MS of 5, a hexasulfated tetrasaccharide, is shown in Figure 2e. The structure of 5 
was determined by combining fragment ions from EDD and CID activation of the [M-5H + 
Na]4− m/z 292.9730. The 2-O-sulfo nonreducing end UA is assigned from the mass of either 
the B1 or C1 fragment. Accurate mass difference between the C2 or B2 and C1 or B1 locates 
2 sulfo groups on the internal GlcN residue. We are able to eliminate the possibility of 3-O-
group on this GlcN unit from the accurate mass of 2,4X2 fragment, which allows the 
assignment of the 2 sulfo groups at the 6-O- and N- positions. The sulfo group on the 
nitrogen is further confirmed by subtracting the mass of the 0,2A2 ion from the B2 ion. Using 
both CID and EDD, we confirmed the presence of the reducing end GlcN residue a 
GlcNS3S6S from cleavages Z1 or Y1. We have included a comprehensive mass list (m/z 
intensity) for all the tetrasaccharides in the accompanying Supplementary Material Tables 
S1–S6.
Characterization of the Tetrasaccharides by NMR Spectroscopy
NMR spectroscopy is essential for assigning the stereochemistry of internal UA residue 
epimeric form within each tetrasaccharide and also confirms the positions of the N-acetyl, 
N- and O-sulfo groups (Figs. 3a–3e). The 4 signals between 4.5 and 5.5 ppm were 
characteristic of the anomeric protons of the tetrasaccharides A, B, C, and D residue, that 
is, non-reducing endA→B→C→Dreducing end. The singlet signal at ~2.0 ppm was assigned to 
the methyl protons of N-acetyl group of the GlcNAc residue. The signal, which had the 
largest chemical shift at ~5.7 ppm and correlated to the carbon signal at 107 ppm in 
heteronuclear single quantum coherence (HSQC) spectra (Supplementary Figs. S4a–S4e), 
was assigned to the H4 proton of the ΔUA residue at the nonreducing end of each 
tetrasaccharide (residue A). The signals, located between 3.2 and 4.5 ppm, were assigned 
Chen et al. Page 5
J Pharm Sci. Author manuscript; available in PMC 2017 August 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
using 1H-1H homonuclear correlation spectroscopy (COSY) to determine connectivity 
around each ring. Beginning with the furthest downfield signal at 5.7 ppm assigned to the 
H4 of ΔUA connectivity to H3, H2 and H1 of the nonreducing end ΔUA in each 
tetrasaccharide were established (Figs. 4a–4e). In the HSQC spectra, the anomeric carbon at 
~91 ppm showing the smallest chemical shift of the 4 anomeric carbons is the C1 of the 
GlcN residue at the reducing end. The anomeric proton (H1) correlating is at the reducing 
end GlcN residue (residue D). The most upfield anomeric signal at 4.5 ppm in the 1H NMR, 
having a coupling constant of 8 Hz, correlates to the C1 signal at ~100.5 ppm. This signal is 
the characteristic of a β-configured GlcA residue in heparin, confirming the epimeric 
structure of the internal UA (residue C). By confirming 3 of the anomeric protons, the 
remaining 1 must correspond to the internal GlcN residue (residue B). Using COSY and 
total correlation spectroscopy (TOCSY), all the remaining saccharide ring protons could be 
assigned through their connectivity to their H1 protons (Supplementary Figs. S5a–S5e). The 
fully assigned 1H and 13C NMR data are presented in Table 2.
Tetrasaccharides 1–5 each showed 4 anomeric protons corresponding to nonreducing end 
ΔUA (A), internal GlcN (B), internal GlcA (C), and reducing end GlcN (D). On account of 
anomerization of the reducing end saccharide, both α- and β-anomeric forms are possible. In 
all 5 heparinase II–resistant tetrasaccharides, the reducing end GlcN is only found in the α-
configuration. This suggests that all of the terminal GlcN residues were substituted with N-
sulfo groups, fixing these residues in the α-configuration. NMR analysis of heparin shows 
that substitution with an N-sulfo group results in a large upfield shift of the H2 of the GlcN 
residue when compared to substitution with an N-acetyl group. This was clearly observed in 
the spectrum of 1, where the H2 of internal GlcNAc residue was at 3.81 ppm, similar to the 
GlcNAcH2 signal reported for heparin, whereas the H2 of the reducing end GlcNS was 
shifted upfield to 3.29 ppm. This evidence also supports the presence of an N-sulfo reducing 
end GlcN residue. Next, the remaining signals of reducing end GlcN (D) and the internal 
GlcN (B) residues were compared. The chemical shifts of the reducing end GlcNSH6a,b and 
C6 were 3.81, 3.73 ppm and 59.8 ppm, respectively, whereas that of internal GlcNAcH6a,b 
and C6 were 4.32, 4.05 ppm and 65.8 ppm, respectively. The downfield shifts of these 
signals of the internal GlcNAc indicate the presence of a 6-O-sulfo group. The H3 of the 
reducing end GlcNS residue was shifted downfield to 4.43 ppm compared to the H3 of 
internal GlcNAc residue at 3.72 ppm, indicating the 3-O-sulfo group was on GlcNS residue 
at the reducing end. Based on these analyses, the structure of 1 was found to be consistent 
with ΔUA-GlcNAc6S-GlcA-GlcNS3S.
The 1D and 2D COSY spectra of 2 are presented in Figs. 3b and 4b. The critical 
characteristics of 2 were similar to 1. No significant differences were observed except for the 
downfield shift in the H6a,b of the reducing end GlcNS (D) by 0.53 and 0.45 ppm, and the 
chemical shifts of H6 and C6 were similar to those of the internal 6-O-sulfoGlcNS (B). So 
both the GlcNS residues of 2 are substituted with 6-O-sulfo groups. The structure of 2 was 
found to be consistent with ΔUA-GlcNAc6S-GlcA-GlcNS3S6S.
The 1D spectrum of 3 showed no resonance for the methyl protons of the acetamido group 
(Fig. 3c), indicating both GlcN (B) and GlcN (D) were substituted with N-sulfo groups. The 
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chemical shift of H2 of GlcNS (B) was 3.18 ppm, consistent with a GlcNS residue. The 
structure of 3 was found to be consistent with ΔUA-GlcNS6S-GlcA-GlcNS3S6S.
The anomeric proton of the ΔUA (A) residue in 4 was shifted downfield from 5.02 ppm to 
5.37 ppm (Fig. 3d). In contrast, the anomeric carbon of the ΔUA (A) residue was shifted 
upfield from 100.7 ppm to 97.0 ppm (Supplementary Fig. S4d). In addition, the H2 signal of 
the ΔUA (A) residue was shifted to 4.5 ppm from 3.65 ppm, almost completely overlapped 
with the H1 proton of GlcA (C). These spectral properties are consistent with the 2-O-sulfo 
group-substitution of the ΔUA (A) residue. Thus, the structure of 4 was found to be 
consistent with ΔUA2S-GlcNAc6S-GlcA-GlcNS3S6S.
The MS and 1D 1H NMR spectra of 5 (Fig. 3e) showed that it had no acetyl group. The H2 
of ΔUA (A) residue also overlapped with anomeric proton of GlcA at 4.5 ppm consistent 
with a nonreducing terminal ΔUA2S. The HSQC spectrum (Supplementary Fig. S4e) 
showed both the GlcNS (B) and GlcNS (D) residues were substituted with 6-O-sulfo groups, 
having chemical shifts for H6 and C6 of >4.0 ppm and 65 ppm, respectively. The H3 of the 
reducing end GlcNS (D) residue of 5 was consistent with the presence of a 3-O-sulfo group. 
Thus, the structure of 5 was found to be consistent with ΔUA2S-GlcNS6S-GlcA-
GlcNS3S6S.
All 5 tetrasaccharides clearly had 3-O-sulfo group substitution of the reducing end GlcNS 
residue, consistent with the known specificity of heparin lyase II resistance.22,27,28 The ΔUA 
at the nonreducing end was either unsubstituted or substituted with 2-O-sulfo groups again 
consistent with the known substrate specificity of heparin lyase II.22,27,28 The internal UA 
was GlcA and no sulfation of this residue was observed. The assignment of the internal 
GlcA was challenging, as we were unable to fully assign this residue. In the COSY, the 
continuous cross-peaks stopped at H3/H4 and no cross-peak for H4/H5 was observed. In the 
TOCSY, no H5 signal could be found and only correlation peaks for H1/H2, H1/H3, and 
H1/H4 were found. This failure might result from the close chemical shifts for H4/H5 and 
C4/C5. These 2 signals are nearly completely overlapped. The internal GlcN residue could 
be substituted with N-acetyl or N-sulfo group but always contained a 6-O-sulfo group.
Standard Curve of Tetrasaccharide Analysis
The most abundant disaccharide formed, when heparin is digested with heparin lyase II, is 
the trisulfated disaccharide, ΔUA2S-GlcNS6S. This disaccharide has a ΔUA2S nonreducing 
terminal residue with a maximum absorbance at 232 nm. The 5 heparin lyase II–resistant 3-
O-sulfo group–substituted tetrasaccharides had either a ΔUA or a ΔUA2S residue, with the 
same absorbance maximum, and between 3 and 6 sulfates. Thus, we selected ΔUA2S-
GlcNS6S as an external standard to quantify these 5 tetrasaccharides. At the range of 0.02 
mg/mL and 0.2 mg/mL, the peak areas of these 5 tetrasaccharides showed good linearity 
between peak area and molar concentration.
The composition of tetrasaccharides having 3-O-sulfo groups was different in heparin 
samples. Thus, tetrasaccharide standards with different ranges of concentration were 
prepared based on the approximate content found in pharmaceutical porcine intestinal 
heparin (1: 64, 128, 192, 256, and 320 ng; 2:128, 256, 384, 512, and 640 ng; 3: 64,128, 50, 
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192, 256, and 320 ng; 4: 16, 32, 48, 64, and 80 ng; 5: 64, 128, 50, 192, 256, and 320 ng). 
These standard mixtures were analyzed by reversed-phase ion pair (RPIP)-HPLC-MS to 
evaluate both the sensitivity and the linearity of tetrasaccharide amount and the peak 
intensities using extracted ion chromatography. The 5 tetrasaccharides showed complete 
separation (Supplementary Fig. S6). The integrated tetrasaccharide peak areas show good 
linearity to their amounts (Supplementary Fig. S7). The 5 tetrasaccharides had different 
ionization efficiencies in an ESI source. Tetrasaccharide 3 showed a greater ionization 
efficiency, which is reflected by the high slope of its standard curve. Tetrasaccharide 5 with 
6 sulfo groups showed the lowest ionization efficiency under the same experimental 
conditions, and 1, 3, and 4 showed comparable intermediate ionization efficiency.
Heparin Lyase II–Resistant 3-O-sulfo Tetrasaccharide Content of Various Heparins and 
LMWHs
Five different heparin samples and 3 different LMWH samples were completely digested 
using heparin lyase II in triplicate and then analyzed by RPIP-HPLC-MS. All of the 5 
resulting 3-O-sulfo tetrasaccharides could be detected and quantified by this method. The 
extracted ion chromatograms showing their tetrasaccharide compositions are presented in 
Figure 5 (see Supplementary Fig. S8 for the supporting chromatogram). Heparin and 
LMWH from different sources contained different contents of heparin lyase II–resistant 3-O-
sulfo tetrasaccharides. The total contents of these 5 tetrasaccharides ranged from 1.0%–
7.0%. The 2 porcine intestinal heparins (USP and SPL2) afforded a total of 6.2% and 5.4% 
3-O-sulfotetrasaccharides. The 3 bovine lung heparins (SPL BL4, Hepar BL2, and Upjohn 
BL6 had the lowest total tetrasaccharide content ranging from 1.1% to 4.4%. 
Tetrasaccharide 2 was the most abundant heparin lyase II–resistant 3-O-sulfo tetrasaccharide 
in all the samples except in BL6, which contained tetrasaccharide 5 as its major component. 
Among the 3 LMWHs, the levels of 1–4 were very similar but major differences in the level 
of 5 were observed.
Correlation Between Anticoagulant Activity and Contents of 3-O-sulfo Group 
Tetrasaccharides
The anticoagulant activity of heparin, particularly its anti-factor Xa activity, is primarily 
ascribed to AT-pentasaccharide binding site. The central residue of this pentasaccharide is a 
3-O-sulfo group–containing GlcN residue. Thus, the 3-O-sulfo tetrasaccharide composition 
and content obtained from heparin lyase II digestion should reflect all the structural variants 
of AT-binding pentasaccharide, correlating to the anticoagulant activity of heparin samples. 
These tetrasaccharides can be sensitively analyzed using RPIP-LC-MS (Fig. 6). Only a weak 
correlation was observed between the anticoagulant activity and the total amount of 3-O-
sulfo group–containing tetrasaccharide content (not shown). Tetrasaccharide 2, the most 
abundant 3-O-sulfo group–containing tetrasaccharide, gave the best linear correlation with 
anticoagulant activity (R2 = 0.96). These results suggest that different 3-O-sulfo group–
containing pentasaccharides may exhibit different anticoagulant activities.
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Conclusions
The AT-binding site shows a substantial variability in heparins derived from animal tissues 
(Fig. 7). Five major variants representing >90% of the 3-O-sulfo group–containing 
sequences have been structurally characterized. Both tetrasaccharide 4 and tetra-saccharide 5 
are newly discovered compounds obtained from heparin lyase II–digested porcine heparin 
and to our knowledge have not been reported by previous publications. In addition, an SAX-
HPLC method has been developed that can quantify all the 5 major 3-O-sulfo group–
containing tetrasaccharides in different heparins. These 5 major variants provide some 
structure-activity relationship for heparin’s anticoagulant activity and provide a deeper 
understanding of the structural variants of the AT-binding site present within heparin. These 
sequences show variability in residues A, B, and D. Residue A, lying outside the AT-binding 
site on its nonreducing end, shows a high level of variability. In this study, it is observed that 
ΔUA and ΔUA2S, based on the known specificity of heparin lyase II,33 could correspond to 
GlcA, IdoA, IdoA2S, and possibly even GlcA2S. The variability of residue B, first reported 
as a major structural difference between porcine and bovine heparin,34 can be GlcNS6S or 
GlcNAc6S. Residue D, containing the critical 3-O-sulfo group, can be GlcNS3S6S or 
GlcNS3S. Interestingly, residue C is invariable and always GlcA. The synthetic 
pentasaccharide, Arixtra®, is the most highly sulfated version of this binding site, 
corresponding to tetrasaccharide 5. It is noteworthy that the content of tetrasaccharide 2, 
which correlates best to heparin’s anticoagulant activity, contains a lower level of sulfation. 
This observation may be important in designing synthetic versions of ultra-low-molecular-
weight heparins and LMWHs. It is well established that heparin-induced thrombocytopenia, 
a major side effect associated with the chemical use of heparin, correlates to both the size of 
the heparin chain and its charge density. This suggests that it might be possible to reduce the 
level of negative charge within the AT-binding site in the design of new synthetic targets. 
Finally, the ability to quantify the AT-binding site variants in animal-sourced heparins and 
LMWHs will assist in our understanding of their biological activities and help us in 
distinguishing the species and organ source of these products. Future studies will be needed 
to establish the structure of additional minor 3-O-sulfo group–containing tetrasaccharides as 
well as those present in bovine and ovine heparins.
Materials and Methods
Materials
Heparin lyase II, originating from Flavobacterium heparinum, was expressed and purified in 
Escherichia coli (no EC assigned) in our laboratory as described previously. Pharmaceutical 
heparins were selected having various levels of anticoagulant activity (units of USP activity) 
from Celsus (Lot: PH-85314), Scientific Protein Laboratories (SPL2, Lot: 1037-3465 and 
BL4, Lot: 002-139), Hepar (BL2, Lot: 38988C), and Upjohn (BL6, Lot: BU3888B). 
LMWHs were from Sanofi-Aventis (Lovenox®, enoxaparin, Lot: 4LM92) Teva (enoxaparin, 
Lot: AB15027), and Sandoz (enoxaparin, Lot: 927791). The ion-pairing reagent 
tributylamine was purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals were 
of HPLC grade.
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Purification of 3-O-sulfo Tetrasaccharides
Tetrasaccharides containing 3-O-sulfo group–substituted GlcN residues at their reducing 
ends are resistant to heparinase.35 A 500-mg heparin sample was dissolved in 100 mL 
digestion buffer (50 mM ammonium acetate, 2 mM calcium chloride) and exhaustively 
digested by heparin lyase 2 (35 IU, activity against heparin) at 37°C for 6 h. After the 
reaction finished, the enzyme was removed by centrifugation (8000 × g) through a 3-kDa 
molecular weight cutoff spin column (50 mL). The filtrate that contained the disaccharide 
and tetrasaccharide products was recovered and freeze-dried.
Buffer salts and most of the disaccharide products were removed by a Bio-Rad P2 column 
(100 × 2.0 cm) eluted at 0.5 mL/min with distilled water. The first peak from the column 
contained primarily tetrasaccharides as confirmed by MS and was collected and lyophilized. 
The tetrasaccharide mixture was fractionated on a semipreparative SAX-HPLC column 
Spherisorb S5 (20 × 250 mm; Waters, Milford, MA). Mobile phase A was water adjusted to 
pH 3.5 with hydrochloric acid and mobile phase B was 2 M aqueous sodium chloride 
adjusted to pH 3.5. A stepwise elution was used with linear gradient of mobile phase B 
(t0–20 min 0%; t20–80 min 0%–20%; t80–120 min 60%) at a flow rate of 4 mL/min. 
Continuous UV detection was performed at 232 nm. The peaks containing tetrasaccharides 
eluted from 120 to 140 min. After desalting by Bio-Rad P2 column, the samples were 
subjected to the second gradient elution: t0–100 min 25%–50% B. The individual peaks 
eluting were collected and desalted by Bio-Rad P2 column and lyophilized.
Every peak was analyzed using MS, and tetrasaccharide-containing peaks were further 
purified by repeated separation on the same SAX-HPLC column to obtain pure samples as 
demonstrated by analytical HPLC. The pure tetrasaccharides were next structurally 
characterized using NMR and MS/MS. Our final recoveries from 500 mg of heparin were 
0.5 mg (5.4%), 0.6 mg (2.7%), 0.2 mg (7.4%), 0.12 mg (2.9%), and 0.12 mg (4.3%) for 
tetrasaccharide 1, 2, 3, 4, and 5, respectively. These recovery yields, based on SAX-HPLC 
analysis of the starting heparin, range from 2.7% to 7.4% and are low because center cuts of 
peaks were taken to optimize the purity (>90%) of each oligosaccharide.
Structure Elucidation by NMR
Freeze-dried tetrasaccharide samples were dissolved in 400 μL D2O (99.96 atom%) and 
lyophilized 2 times to remove exchangeable protons and transferred to an NMR tube (d = 5 
mm). 1H NMR, HSQC NMR, 1H-1HCOSY, and TOCSY were performed on a Bruker 800-
MHz NMR spectrometer, and acquisition of the spectra was carried out using Topspin 2.1.6 
software. All spectra were acquired at a temperature of 298 K.
Structural Analysis by MS/MS
MS/MS analysis of the 3-O-sulfo tetrasaccharides was performed on a 9.4T Bruker Apex 
Ultra Qh-FTICR instrument (Billerica, MA) fitted with an indirectly heated hollow cathode 
(HeatWave, Watsonville, CA) for electron generation. Each tetrasaccharide (0.1 mg/mL) in 
50:50 methanol/H2O was infused at a rate of 120 μL/h and ionized by ESI using a metal 
capillary (Agilent Technologies, Santa Clara, CA, #G2427A). Multiply charged precursor 
ions were isolated in the external quadruple and activated using CID in the collision cell and 
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EDD in the infinity cell. Also, 512 K points were acquired for each spectra and padded with 
1 zero fill and apodized sinebell window. External calibration produced a 5-ppm mass 
accuracy, and using confidently assigned glycosidic bond cleavage product ions, internal 
calibration yielded mass accuracy mostly less than 1 ppm. All MS/MS product ions are 
reported using the Domon and Costello321998 nomenclature.
Enzymatic Digestion of Heparin and LMWH
Heparin and LMWH samples (200 μg) were dissolved in 100 μL of digestion buffer (50 mM 
ammonium acetate, 2 mM calcium chloride) and digested by heparin lyase II (20 mU) at 
37°C for 6 h. The digestion solutions were immediately heated in a 100°C water bath for 5 
min to stop the reaction and precipitate proteins. The supernatant was obtained after 
centrifugation for 15 min (16,000 × g).
Quantity of the Tetrasaccharides by SAX-HPLC
Purified tetrasaccharides were quantified using SAX-HPLC coupling with an analytical 
Spherisorb S5 (4 × 250 mm; Waters, Milford, MA) at 232 nm. Mobile phase A: 1.8 mM 
monobasic sodium phosphate, pH 3.0. Mobile phase B: 1.8 mM monobasic sodium 
phosphate, 1 M sodium perchlorate, pH 3.0. Flow rate: 0.45 mL/min. Gradient: T0–35 min, 
30%–65% B; T35–50 min, 65%–85% B. ΔUA2S-GlcNS6S with different concentrations 
(0.02–0.2 mg/mL) were used as the standard. The linearity was based on amount of peak 
areas in HPLC.
Reversed-Phase Ion Pair-HPLC-MS
Liquid chromatography-mass spectrometry (LC-MS) analyses were performed on an Agilent 
1200 LC/MSD instrument (Agilent Technologies, Wilmington, DE) equipped with a 6300 
ion trap. The column used was a Poroshell 120 C18 column (2.1 × 100 mm, 2.7 μm; Agilent 
Technologies). Eluent A was water/acetonitrile (85:15, v/v), and eluent B was water/
acetonitrile (35:65, v/v). Both eluents contained 12 mM tributylamine and 38 mM NH4OAc 
with pH adjusted to 6.5 with HOAc. A gradient of solution A for 2 min, followed by a linear 
gradient of 0% to 30% solution B from 2 to 40 min, and 30% to 60% solution B from 40 to 
50 min was used at a flow rate of 120 μL/min. The column effluent entered the source of the 
ESI-MS for continuous detection by MS. The electrospray interface was set in negative 
ionization mode with a skimmer potential of −40.0 V, a capillary exit of −40.0 V, and a 
source temperature of 350°C to obtain the maximum abundance of the ions in a full scan 
spectrum (200–1500 Da). Nitrogen was used as a drying (8 L/min) and nebulizing (40 psi) 
gas.
Calibration
Quantification analysis of 3-O-sulfo group–containing tetrasaccharides was performed by 
using calibration curves constructed by increasing amounts of produced tetrasaccharide 
standards. The linearity was based on peak intensity in MS. All analyses were performed in 
triplicate.
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Abbreviations used
AT antithrombin III
UA uronic acid
IdoA iduronic acid
GlcA β-D-glucuronic acid
GlcN α-D-glucosamine
STs sulfotransferases
NDST N-sulfotransferase
3OST 3-O-sulfotransferase
6OST 6-O-sulfotransferase
2OST 2-O-sulfotransferase
LMWH low-molecular-weight heparin
MS mass spectrometry
MS/MS tandem MS
NMR nuclear magnetic resonance spectroscopy
HPLC high-performance liquid chromatography
ΔUA deoxy-α-L-threo-hex-4-enopyranosyluronic acid
SAX strong anion exchange
S sulfo
CID collisionally induced dissociation
EDD electron-detachment dissociation
HSQC heteronuclear single quantum coherence
COSY 1H-1H homonuclear correlation spectroscopy
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TOCSY total correlation spectroscopy
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Figure 1. 
SAX-HPLC of the crude tetrasaccharides recovered from size-exclusion chromatography 
(Supplementary Fig. S1). (a) A linear gradient of mobile phase B (t0–20 min 0%; t20–80 min 
0%–20%; t80–120 min 60%) was applied to separate the tetrasaccharides from other 
components of the mixture. The structures of tetrasaccharides 1–5 are shown in Figures 2 
and 3. The structure of TriS is ΔUA2S-GlcNS6S. (b) After desalting the tetrasaccharides, the 
sample was again applied to the column using an optimized gradient of mobile phase B 
(t0–100 min 25%–50%) to recover individual tetrasaccharides. Detection relied on UV 
absorbance at 232 nm.
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Figure 2. 
MS/MS structural annotations for CID of 1 ΔUA-GlcNAc6S-GlcA-GlcNS3S; EDD of 2 
ΔUA-GlcNAc6S-GlcA-GlcNS3S6S; CID of 3 ΔUA-GlcNS6S-GlcA-GlcNS3S6S; CID of 4 
ΔUA2S-GlcNAc 6S-GlcA-GlcNS3S6S; and CID/EDD of 5 ΔUA2S-GlcNS6S-GlcA-
GlcNS3S.
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Figure 3. 
Structures and 1D 1H NMR spectra of 1–5 are shown in panels (a–e) respectively.
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Figure 4. 
The COSY spectra of 1–5 are shown in panels (a–e) respectively.
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Figure 5. 
Composition and contents of tetrasaccharides 1–5 of heparins and LMWHs (see 
Supplementary Fig. S8 for the supporting chromatogram).
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Figure 6. 
Correlation between anticoagulant activity and the content of 3-O-sulfo group–containing 
tetrasaccharide 2.
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Figure 7. 
Structural variability of AT-binding site (residues A–F). The substituents shown in red and 
blue are found within and adjacent to the AT-binding site in heparins derived from animal 
tissues. The carboxyl group shown in purple can be axial or equatorial for recognition and 
cleavage by heparin lyase II.
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